| Autor: |
Alfano, Simon, Amberg, Christian, Peters, Nils, Salazar, Pablo, Rochas, Marianne Vieux, Welton, Sam |
| Předmět: |
|
| Zdroj: |
McKinsey Insights; 2/27/2023, pN.PAG-N.PAG, 1p |
| Abstrakt: |
Notably, the inherently small sample size of patients who suffer from rare diseases is a shift from the broader patient segments for which treatments were historically created. For example, one global pharmaceutical company with a sizable rare disease operation deployed digital and analytics to improve its patient-finding approach for one of its rare-disease treatments. One treatment for a chronic rare disease, for example, leverages a mobile app for symptom tracking and personalized dosing recommendations, allowing patients to share their data with their healthcare provider for an optimized treatment algorithm. Harnessing the power of analytics to engage when and where it matters most for HCPs and pa... Compared with other disease areas, the rare disease space is often characterized by close connections within the community of patients, caregivers, and patient associations. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
